Past and future. Current drugs targeting HIV-1 integrase and reverse transcriptase-associated ribonuclease H activity: Single and dual active site inhibitors

Antiviral Chemistry and Chemotherapy

Volumn 23, Issue 4, 2014, Pages 129-144

  Esposito, Francesca ^a   Tramontano, Enzo ^a  

^a UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

1 [5 (4 FLUOROBENZYL) 2 FURYL] 3 (1,2,4 TRIAZOL 3 YL) 1,3 PROPANEDIONE; DOLUTEGRAVIR; ELVITEGRAVIR; INTEGRASE; INTEGRASE INHIBITOR; RALTEGRAVIR; RIBONUCLEASE H; RIBONUCLEASE INHIBITOR;

DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME STRUCTURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW;

CATALYTIC DOMAIN; DRUG DISCOVERY; HIV INFECTIONS; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MODELS, MOLECULAR; RIBONUCLEASE H;

EID: 84893202040     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP2690     Document Type: Review

References (109)

1. Nowotny M. Retroviral integrase superfamily: the structural perspective. EMBO Rep 2009; 10:144-151.
2. Goldgur Y, Dyda F, Hickman AB, Jenkins TM, Craigie R, Davies DR. Three new structures of the core domain of HIV-1 integrase: an active site that binds magnesium. Proc Natl Acad Sci U S A 1998; 95:9150-9154.
3. Peletskaya EN, Kogon AA, Tuske S, Arnold E, Hughes SH. Nonnucleoside inhibitor binding affects the interactions of the fingers subdomain of human immunodeficiency virus type 1 reverse transcriptase with DNA. J Virol 2004; 78:3387-3397.
4. Dyda F, Hickman AB, Jenkins TM, et al. Crystal structure of the catalytic domain of HIV-1 integrase: similarity to other polynucleotidyl transferases. Science 1994; 266:1981-1986.
5. Grinsztejn B, Nguyen BY, Katlama C, et al. Safety and efficacy of the HIV-1 integrase inhibitor raltegavir (MK-0518) in treatment-experienced patients with multidrugresistant virus: a Phase II randomized controlled trial. Lancet 2007; 369:1261-1269.
6. Sato M, Motomura T, Aramati H, et al. Novel HIV-1 integrase inhibitors derived from quinolone antibiotics. J Med Chem 2006; 49:1506-1508.
7. Xue W, Jin X, Ning L, et al. Exploring the molecular mechanism of cross-resistence to HIV-1 integrase strand transfer inhibitors by molecular dynamics simulation and residue interaction network analysis. J Chem Inf Model 2013; 53:210-222.
8. Tramontano E. HIV-1 RNase H: recent progress in an exciting, yet little explored, drug target. Mini Rev Med Chem 2006; 6:727-737.
9. Tramontano E, Di Santo R. HIV-1 RT-associated RNase H function inhibitors: recent advances in drug development. Curr Med Chem 2010; 17:2837-2853.
10. Distinto S, Maccioni E, Meleddu R, et al. Molecular aspects of the RT/drug interactions. Perspective of dual inhibitors. Curr Pharm Des 2013; 19:1850-1859.
11. Ellison V, Gerton J, Vincent KA, Brown PO. An essential interaction between distinct domains of HIV-1 integrase mediates assembly of the active multimer. J Biol Chem 1995; 270:3320-3326.
12. Faure A, Calmels C, Desjobert C, et al. HIV-1 integrase crosslinked oligomero are active in vitro. Nucleic Acids Res 2005; 33:977-986.
13. Guiot E, Carayon K, Delelis O, et al. Relationship between the oligomeric status of HIV-1 integrase on DNA and enzymatic activity. J Biol Chem 2006; 281:22707-22719.
14. De Luca A, Antinori A, Di Gianbenedetto S, et al. Interpretation systems for genotypic drug resistance of HIV-1. Scand J Infect Dis Suppl 2003; 53:29-34.
15. Esposito D, Craigie R. Sequence specificity of viral end DNA binding by HIV-1 integrase reveals critical region for protein-DNA interaction. EMBO J 1998; 17:5832-5843.
16. Miller MD, Farnet CM, Bushman FD. Human immunodeficiency virus type 1 preintegration complexes: studies of organization and composition. J Virol 1997; 71:5382-5390.
17. Farnet CM, Haseltine WA. Determination of viral proteins present in the human immunodeficiency virus type 1 preintegration complex. J Virol 1991; 65:1910-1915.
18. Vanegas M, Llano M, Delgado S, Thompson D, Peretz M, Poeschla E. Identification of the LEDGF/p75 HIV-1 integrase-interaction domain and NLS reveals NLSindependent chromatin tethering. J Cell Sci 2005; 118:1733-1743.
19. Rice P, Craigie R, Davies D. Retroviral integrases and their cousins. Curr Opin Struct Biol 1996; 6:76-83.
20. Polard P, Chandler M. Bacterial transposases and retroviral integrases. Mol Microbiol 1995; 15:13-23.
21. Burke CJ, Sanyal G, Bruner M, et al. Structural implications of spectroscopic characterization of a putative zinc finger peptide from HIV-1 integrase. J Biol Chem 1992; 267:9639-9644.
22. 2+ promotes the self-association of HIV-1 integrase in vitro. Biochemistry 1997; 36:173-180.
23. Zheng R, Jenkins T, Craigie R. Zinc folds the N-terminal domain of HIV-1 integrase, promotes multimerization, and enhances catalytic activity. Proc Natl Acad Sci U S A 1996; 93:13659-13664.
24. Bouiac-Bertoia M, Dvorin J, Fouchier R, et al. HIV-1 infection require a functional integrase NLS. Mol Cell 2001; 7:1025-1035.
25. Berthoux L, Sebastian S, Muesing M, Luban J. The role of lysine 186 in HIV-1 integrase multimerization. Virology 2007; 364:227-236.
26. Cherepanov P, Maertens G, Proost P, et al. HIV-1 integrase forms stable tetramers and associates with LEDGF/p75 protein in human cells. J Biol Chem 2003; 278:372-381.
27. Ciuffi A, Llano M, Poeschla E, et al. A role for LEDGF/ p75 in targeting HIV DNA integration. Nat Med 2005; 11:1287-1289.
28. Wang JY, Ling H, Yang W, Craigie R. Structure of a twodomain fragment of HIV-1 integrase: implications for domain organization in the intact protein. EMBO J 2001; 20:7333-7343.
29. Llano M, Saenz DT, Meehan A, et al. An essential role for LEDGF/p75 in HIV integration. Science 2006; 314:461-464.
30. Engelman A, Hikman A, Craigie R. The core and carboxyl-terminal domains of integrase protein of HIV-1 each contribute to non-specific DNA binding. J Virol 1994; 68:5911-5917.
31. Lutzke RA, Plasterk R. Structure-based mutational analysis of the C-terminal DNA binding domain of HIV-1 integrase: critical residues for protein oligomerization and DNA binding. J Virol 1998; 72:4841-4848.
32. Lutzke RA, Vink C, Plasterk R. Characterization of the minimal DNA-binding domain of the HIV integrase protein. Nucleic Acids Res 1994; 22:4125-4131.
33. Vink C, Oude Groeneger A, Plasterk R. Identification of the catalytic and DNA-binding region of the HIV-1 integrase protein. Nucleic Acids Res 1993; 21:1419-1425.
34. Engelman A, Mizuuchi K, Craigie R. HIV-1 DNA integration: mechanism of viral DNA cleavage and DNA transter. Cell 1991; 67:1211-1221.
35. Mulder LC, Chakrabarti L, Muesing M. Interaction of HIV-1 integrase with DNA repair protein hRad18. J Biol Chem 2002; 277:27489-27493.
36. Yoder KE, Bushman F. Repair of gaps in retroviral DNA integration intermediates. J Virol 2000; 74:11191-11200.
37. Hare S, Gupta SS, Valkov E, Engelman A, Cherepanov P. Retroviral intasome assembly and inhibition of DNA strand transfer. Nature 2010; 464:232-236.
38. Esposito F, Corona A, Tramontano E. HIV-1 reverse transcriptase still remains a new drug target: structure, function, classical inhibitors, and new inhibitors with innovative mechanism of actions. Mol Biol Intern 2012; 2012:586401.
39. Kohlstaedt LA, Wang J, Friedman JM, Rice PA, Steitz TA. Crystal structure at 3.5 Å resolution of HIV-1 reverse transcriptase complexes with an inhibitor. Science 1992; 256:1783-1790.
40. Jacobo-Molina A, Ding J, Nanni R, et al. Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 A resolution shows bent DNA. Proc Natl Acad Sci U S A 1993; 90:6320-6324.
41. Nowotny M, Gaidamakov SA, Crouch RJ, Yang W. Crystal structures of RNase H bound to an RNA/DNA hybrid: substrate specificity and metal-dependent catalysis. Cell 2005; 121:1005-1016.
42. Beilhartz GL, Götte M. HIV-1 ribonuclease H: structure, catalytic mechanism and inhibitors. Viruses 2010; 2:900-926.
43. Mizrahi V, Usdin MT, Harington A, Dudding LR. Sitedirected mutagenesis of the conserved Asp-443 and Asp-498 carboxy-terminal residues of HIV-1 reverse transcriptase. Nucleic Acids Res 1990; 18:5359-5363.
44. Hazuda DJ, Felock P, Witmer M, et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 2000; 287:646-650.
45. Marchand C, Zhang X, Pais GC, et al. Structural determinants for HIV-1 integrase inhibition by beta-diketo acids. J Biol Chem 2002; 277:12596-12603.
46. Reinke R, Lee DJ, Robinson WE. Inhibition of human immunodeficiency virus type 1 isolates by the integrase inhibitor L-731,988, a diketo acid. Antimicrob Agents Chemother 2002; 46:3301-3303.
47. Goldgur Y, Craigie R, Cohen GH, et al. Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: a platform for antiviral drug design. Proc Natl Acad Sci U S A 1999; 96:13040-13043.
48. Billich A. S-1360 Shionogi-GlaxoSmithKline. Curr Opin Investig Drugs 2003; 4:206-209.
49. Anthony NJ. HIV-1 integrase: a target for new AIDS chemotherapeutics. Curr Top Med Chem 2004; 4:979-990.
50. Burger DM. Raltergravir: a review of its pharmacokinetics, pharmacology and clinical studies. Expert Opin Drug Metab Toxicol 2010; 6:1151-1160.
51. Krishnan L, Li X, Naraharisetty HL, Hare S, Cherepanov P, Engelman A. Structure-based modeling of the functional HIV-1 intasome and its inhibition. Proc Natl Acad Sci U S A 2010; 107:15910-15915.
52. Métifiot M, Marchand C, Maddali K, Pommier Y. Resistance to integrase inhibitors. Viruses 2010; 2:1347-1366.
53. Pendri A, Meanwell NA, Peese KM, Walker MA. New first and second generation inhibitors of human immunodeficiency virus-1 integrase. Expert Opin Ther Pat 2011; 21:1173-1189.
54. De Jesus E. Antiretroviral agents in development. (Updated 30 March 2006. Accessed 10 August 2013.) Available from http://www.thebody.com/content/art1352.html
55. Blanco JL, Varghese V, Rhee SY, Gatell JM, Shafer RW. HIV-1 integrase inhibitor resistance and its clinical implications. J Infect Dis 2011; 203:1204-1214.
56. Shimura K, Kodama E, Sakagami Y, et al. Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor eltvitegravir (JTK-303/SG-9137). J Virol 2008; 82:764-774.
57. Fantauzzi A, Turriziani O, Mezzaroma I. Potential benefit of dolutegravir once daily: efficacy and safety. HIV AIDS (Auckl) 2013; 5:29-40.
58. Al-Mawsawi LQ, Al-Safi RI, Neamati N. Anti-infectives: clinical progress of HIV-1 integrase inhibitors. Expert Opin Emerg Drugs 2008; 13:213-225.
59. Goethals O, van Ginderen M, Vos A, et al. Resistance to raltegavir highlights integrase mutations at codon 148 in conferring cross-resistance to a second-generation HIV-1 integrase inhibitor. Antiviral Res 2011; 91:167-176.
60. Bar-Magen T, Sloan RD, Donahue DA, et al. Identification of novel mutations responsible for resistance to MK-2048, a second-generation HIV-1 integrase inhibitor. J Virol 2010; 84:9210-9216.
61. Summa V, Petrocchi A, Matassa VG, et al. 4, 5-Dihydroxypyrimidine carboxamides and N-alkyl-5-hydroxypyrimidinone carboxamides are potent, selective HIV integrase inhibitors with good pharmacokinetic profiles in preclinical species. J Med Chem 2006; 49:6646-6649.
62. Pace P, Di Francesco ME, Gardelli C, et al. Dihydroxypyrimidine-4-carboxamides as novel potent and selective HIV integrase inhibitors. J Med Chem 2007; 50:2225-2239.
63. Petrocchi A, Koch U, Matassa VG, Pacini B, Stillmock KA, Summa V. From dihydroxypyrimidine carboxylic acids to carboxamide HIV-1 integrase inhibitors: SAR around the amide moiety. Bioorg Med Chem Lett 2007; 17:350-353.
64. Dayam R, Al-Mawsawi LQ, Neamati N. Substituted 2-pyrrolinone inhibitors of HIV-1 integrase. Bioorg Med Chem Lett 2007; 17:6155-6159.
65. Ma K, Wang P, Fu W, et al. Rational design of 2-pyrrolinones as inhibitors of HIV-1 integrase. Bioorg Med Chem Lett 2011; 21:6724-6727.
66. Pendri A, Troyer TL, Sofia MJ, et al. Solid phase synthesis of a novel pyrrolidinedione analogs as potent HIV-1 integrase inhibitors. J Comb Chem 2010; 12:84-90.
67. Sriram D, Yogeeswari P, Senchani G, Banerjee D. Newer tetracycline derivatives: synthesis, anti-HIV, antimycobacterial activities and inhibition of HIV-1 integrase. Bioorg Med Chem Lett 2007; 17:2372-2375.
68. Zouhiri F, Mouscadet JF, Mekouar K, et al. Structureactivity relationships and binding mode of styrylquinolines as potent inhibitors of HIV-1 integrase and replication of HIV-1 in cell culture. J Med Chem 2000; 43:1533-1540.
69. Ouali M, Laboulais C, Leh H, et al. Modeling of the inhibition of retroviral integrases by styrylquinoline derivatives. J Med Chem 2000; 43:1949-1957.
70. Yoo H, Lee JY, Park JH, Chung BY, Lee YS. Synthesis of styrylbenzofuran derivatives as styrylquinoline analogues for HIV-1 integrase inhibitor. Farmaco 2003; 58:1243-1250.
71. Mouscadet J-F, Desmaele D. Chemistry and structureactivity relationship of the styrylquinoline-type HIV integrase inhibitors. Molecules 2010; 15:3048-3078.
72. Zhao XZ, Semenova EA, Vu BC, et al. 2,3-Dihydro-6,7-dihydroxy-1H-isoindol-1-one-based HIV-1 integrase inhibitors. J Med Chem 2008; 51:251-259.
73. Zhao XZ, Maddali K, Smith SJ, et al. 6,7-Dihydroxy-1-oxoisoindoline-4-sulfonamide-containing HIV-1 integrase inhibitors. Bioorg Med Chem Lett 2012; 22:7309-7313.
74. Brzozowski Z, Saczewski F, Slawinski J, Sanchez T, Neamati N. Synthesis and anti-HIV-1 integrase activities of 3-aroyl-2,3-dihydro-1,1-dioxo-1,4,2-benzodithiazines. Eur J Med Chem 2009; 44:190-196.
75. Bransová J, Brtko J, Uher M, Novotny L. Antileukemic activity of 4-pyranone derivatives. Int J Biochem Cell Biol 1995; 27:701-706.
76. Gupta SP, Babu MS, Kaw NJ. Quantitative structure-activity relationships of some HIV-protease inhibitors. J Enzym Inhib 1999; 14:109-123.
77. Ramkumar K, Tambov KV, Gundla R, Manaev AV, Yarovenko V. Discovery of 3-acetyl-4-hydroxy-2-pyranone derivatives and their difluoridoborate complexes as a novel class of HIV-1 integrase Inhibitors. Bioorg Med Chem 2008; 16:8988-8998.
78. Hadi V, Koh Y-H, Sanchez TW, Barrios D, Neamati N, Jung KW. Development of the next generation of HIV-1 integrase inhibitors: Pyrazolone as a novel inhibitor scaffold. Bioorg Med Chem Lett 2010; 20:6854-6857.
79. Zhao XZ, Maddali K, Metifiot M, et al. Bicyclic hydroxy-1H-pyrrolopyridine-trione containing HIV-1 integrase inhibitors. Chem Biol Drug Des 2012; 79:157-165.
80. Johns BA, Weatherhead JG, Allen SH, Thompson JB, Garvey EP, Foster SA. The use of oxadiazole and triazole substituted naphthyridines as HIV-1 integrase inhibitors. Part 1: Establishing the pharmacophore. Bioorg Med Chem Lett 2009; 19:1802-1806.
81. Korolev SP, Kondrashina OV, Druzhilovsky DS, et al. Structural-functional analysis of 2,1,3-benzoxadiazoles and their N-oxides as HIV-1 integrase inhibitors. Acta Naturae 2013; 5:63-72.
82. Maurin C, Lion C, Bailly F, et al. New 2-arylnaphthalenediols and triol inhibitors of HIV-1 integrase-discovery of a new polyhydroxylated antiviral agent. Bioorg Med Chem 2010; 18:5194-5201.
83. Parkes KEB, Ermert P, Fässler J, et al. Use of a pharmacophore model to discover a new class of influenza endonuclease inhibitors. J Med Chem 2003; 46:1153-1164.
84. Klumpp K, Hang JQ, Rajendran S, et al. Two-metal ion mechanism of RNA cleavage by HIV RNase H and mechanism-based design of selective HIV RNase H inhibitors. Nucleic Acids Res 2003; 31:6852-6859.
85. Hang JQ, Rajendran S, Yang Y, et al. Activity of the isolated HIV RNase H domain and specific inhibition by N-hydroxyimides. Biochem Biophys Res Commun 2004; 317:321-329.
86. Billamboz M, Bailly F, Barreca ML, et al. Design, synthesis, and biological evaluation of a series of 2-hydroxyisoquinoline-1,3(2H,4H)-diones as dual inhibitors of human immunodeficiency virus type 1 integrase and the reverse transcriptase RNase H domain. J Med Chem 2008; 51:7717-7730.
87. Billamboz M, Bailly F, Lion C, et al. Magnesium chelating 2-hydroxyisoquinoline-1,3(2H,4H)-diones, as inhibitors of HIV-1 integrase and/or the HIV-1 reverse transcriptase ribonuclease H domain: discovery of a novel selective inhibitor of the ribonuclease H function. J Med Chem 2011; 54:1812-1824.
88. Tomassini J, Selnick H, Davies ME, et al. Inhibition of cap (m7GpppXm)-dependent endonuclease of influenza virus by 4-substituted 2,4-dioxobutanoic acid compounds. Antimicrob Agents Chemother 1994; 38:2827-2837.
89. Shaw-Reid CA, Munshi V, Graham P, et al. Inhibition of HIV-1 ribonuclease H by a novel diketo acid, 4-[5-(benzoylamino)thien-2-yl]-2,4-dioxobutanoic acid. J Biol Chem 2003; 278:2777-2780.
90. Klumpp K, Mirzadegan T. Recent progress in the design of small molecule inhibitors of HIV RNase H. Curr Pharm Des 2006; 12:1909-1922.
91. Shaw-Reid C, Feuston B, Munshi V, et al. Dissecting the effects of DNA polymerase and ribonuclease H inhibitor combinations on HIV-1 reverse-transcriptase activities. Biochemistry 2005; 44:1595-1606.
92. Costi R, Di Santo R, Artico M, et al. 2,6-Bis (3,4,5-trihydroxybenzylydene) derivatives of cyclohexanone: novel potent HIV-1 integrase inhibitors that prevent HIV-1 multiplication in cell-based assays. Bioorg Med Chem 2004; 12:199-215.
93. Costi R, Di Santo R, Artico M, et al. 6-Aryl-2,4-dioxo-5-hexenoic acids, novel integrase inhibitors active against HIV-1 multiplication in cell-based assays. Bioorg Med Chem Lett 2004; 14:1745-1749.
94. Tramontano E, Esposito F, Badas R, Di Santo R, Costi R, La Colla P. 6-[1-(4-Fluorophenyl)methyl-1H-pyrrol-2-yl)]-2,4-dioxo-5-hexenoic acid ethyl ester a novel diketo acid derivative which selectively inhibits the HIV-1 viral replication in cell culture and the ribonuclease H activity in vitro. Antiviral Res 2005; 65:117-124.
95. Budihas SR, Gorshkova I, Gaidamakov S, et al. Selective inhibition of HIV-1 reverse transcriptase-associated ribonuclease H activity by hydroxylated tropolones. Nucleic Acids Res 2005; 33:1249-1256.
96. Semenova EA, Johnson AA, Marchand C, Davis DA, Yarchoan R, Pommier Y. Preferential inhibition of the magnesium-dependent strand transfer reaction of HIV-1 integrase by alpha-hydroxytropolones. Mol Pharmacol 2006; 69:1454-1460.
97. Beilhartz GL, Wendeler M, Baichoo N, Rausch J, Le Grice S, Gotte M. HIV-1 reverse transcriptase can simultaneously engage its DNA/RNA substrate at both DNA polymerase and RNase H active sites: implications for RNase H inhibition. J Mol Biol 2009; 388:462-474.
98. Himmel DM, Maegley KA, Pauly TA, et al. Structure of HIV-1 reverse transcriptase with the inhibitor beta-Thujaplicinol bound at the RNase H active site. Structure 2009; 17:1625-1635.
99. Didierjean C, Isel C, Querré F, et al. Inhibition of human immunodeficiency virus type 1 reverse transcriptase, RNase H and integrase activities byhydroxytropolones. Antimicrob Agents Chemother 2005; 49:4884-4894.
100. Hazuda DJ, Anthony NJ, Gomez RP, et al. A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase. Proc Natl Acad Sci U S A 2004; 101:11233-11238.
101. Su HP, Yan Y, Prasad GS, et al. Structural basis for the inhibition of RNase H activity of HIV-1 reverse transcriptase by RNase H active site-directed inhibitors. J Virol 2010; 84:7625-7633.
102. Williams PD, Staas DD, Venkatraman S, et al. Potent and selective HIV-1 ribonuclease H inhibitors based on a 1-hydroxy-1,8-naphthyridin-2(1H)-one scaffold. Bioorg Med Chem Lett 2010; 20:6754-6757.
103. Kirschberg TA, Balakrishnan M, Squires NH, et al. RNase H active site inhibitors of human immunodeficiency virus type 1 reverse transcriptase: design, biochemical activity, and structural information. J Med Chem 2009; 52:5781-5784.
104. Lansdon EB, Liu Q, Leavitt SA, et al. Structural and binding analysis of pyrimidinol carboxylic acid and N-hydroxy quinazolinedione HIV-1 RNase H inhibitors. Antimicrob Agents Chemother 2011; 55:2905-2915.
105. Fuji H, Urano E, Futahashi Y, et al. Derivatives of 5-nitro-furan-2-carboxylic acid carbamoylmethyl ester inhibit RNase H activity associated with HIV-1 reverse transcriptase. J Med Chem 2009; 52:1380-1387.
106. Yanagita H, Urano E, Matsumoto K, et al. Structural and biochemical study on the inhibitory activity of derivatives of 5-nitro-furan-2-carboxylic acid for RNase H function of HIV-1 reverse transcriptase. Bioorg Med Chem 2011; 19:816-825.
107. Suchaud V, Bailly F, Lion C, et al. Development of a series of 3-hydroxyquinolin-2(1H)-ones as selective inhibitors of HIV-1 reverse transcriptase associated RNase H activity. Bioorg Med Chem Lett 2012; 22:3988-3992.
108. Di Grandi M, Olson M, Prashad AS, et al. Small molecule inhibitors of HIV RT Ribonuclease H. Bioorg Med Chem Lett 2010; 20:398-402.
109. Lapkouski M, Tian L, Miller JT, Le Grice SFJ, Yang W. Complexes of HIV-1 RT, NNRTI and RNA/DNA hybrid reveal a structure compatible with RNA degradation. Nat Struct Mol Biol 2013; 20:230-236.